Apimeds Pharmaceuticals US, Inc. 8-K

What Happened

• Apimeds Pharmaceuticals US, Inc. (the Company) filed a Form 8‑K reporting that on May 4, 2026 the Board, following a stockholder nomination, appointed Sungjoon Chae to serve as Co‑Chief Executive Officer, effective that date. The appointment was made with no other arrangements or understandings disclosed.

Key Details

• Appointment date: May 4, 2026 (reported on Form 8‑K filed May 5, 2026).
• Title: Co‑Chief Executive Officer; nomination by a stockholder.
• Compensation: Material terms not yet determined; Company will disclose once finalized.
• Related‑party disclosures: No family relationships with Company officers or directors; no related party transactions requiring disclosure under Item 404(a) of Regulation S‑K.
• Background: Mr. Chae holds a Master of Architecture in Urban Design from Harvard (2013) and has experience in large‑scale real estate development, urban regeneration, and multidisciplinary project delivery in South Korea and the U.S.

Why It Matters

• This filing reports a leadership change (Item 5.02) that could affect strategy and operations; investors should note the addition of a co‑CEO and await further disclosures on his role, responsibilities and compensation. The company states there are no disclosed related‑party issues, and further material information will be provided when compensation and other terms are finalized.